Patents by Inventor Remko Albert Griep
Remko Albert Griep has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399391Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: January 5, 2023Publication date: December 14, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine lmhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Publication number: 20230227543Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 31, 2023Publication date: July 20, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thoms Regula, Werner Scheuer
-
Patent number: 11685773Abstract: The present invention relates to a method for producing a population of 20 or more nucleic acids, each encoding at least one protein comprising at least one immunoglobulin variable domain having a rabbit-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.Type: GrantFiled: April 29, 2016Date of Patent: June 27, 2023Assignees: ABCHECK s.r.o., CHARLES RIVER LABORATORIES, INC.Inventors: Jacob E. Gunn Glanville, Vera Molkenthin, Remko Albert Griep, Ahmad Trad, Peter Milovnik, Volker Lang
-
Publication number: 20210388071Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: April 5, 2021Publication date: December 16, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20210047394Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 13, 2020Publication date: February 18, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Publication number: 20200262904Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: September 26, 2019Publication date: August 20, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20180319869Abstract: The present invention relates to a method for producing a population of 20 or more nucleic acids, each encoding at least one protein comprising at least one immunoglobulin variable domain having a rabbit-derived CDR3 amino acid sequence embedded in essentially human framework sequences, as well as to a population of nucleic acids and a population of proteins relates thereto and uses thereof.Type: ApplicationFiled: April 29, 2016Publication date: November 8, 2018Inventors: Jacob E. Gunn GLANVILLE, Vera MOLKENTHIN, Remko Albert GRIEP, Ahmad TRAD, Peter MILOVNIK, Volker LANG
-
Publication number: 20180282404Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: February 28, 2018Publication date: October 4, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20170369566Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: May 23, 2017Publication date: December 28, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Patent number: 9708396Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: February 27, 2014Date of Patent: July 18, 2017Assignee: HOFFMANN-LA ROCHE INC.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Publication number: 20170029493Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: April 12, 2016Publication date: February 2, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Patent number: 9458238Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: October 16, 2014Date of Patent: October 4, 2016Assignee: Cancer Research Technology LimitedInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Patent number: 9340609Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.Type: GrantFiled: December 4, 2012Date of Patent: May 17, 2016Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20150284457Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: June 4, 2015Publication date: October 8, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Patent number: 9109027Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2).Type: GrantFiled: July 13, 2012Date of Patent: August 18, 2015Assignee: Hoffman-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Patent number: 9073986Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: February 6, 2013Date of Patent: July 7, 2015Assignee: Hoffman-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20150104831Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: ApplicationFiled: October 16, 2014Publication date: April 16, 2015Applicant: AFFITECH RESEARCH ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovic Kiprijanov
-
Publication number: 20150004166Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: February 27, 2014Publication date: January 1, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Patent number: 8895007Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.Type: GrantFiled: December 7, 2011Date of Patent: November 25, 2014Assignee: Affitech Research ASInventors: Urs Beat Hagemann, Remko Albert Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
-
Patent number: 8703130Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: August 9, 2012Date of Patent: April 22, 2014Assignee: Hoffmann-La Roche, Inc.Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas